Therapeutic compositions comprising imidazole and imidazolium compounds
View Patent ↗Therapeutic compositions comprising at least two substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
1. A method of treating pain, comprising administering a dosage form to a mammal in need thereof, comprising:
and
wherein each A is independently an acidic functional group.
2. The method of claim 1 , wherein each A is CO 2 H.
3. The method of claim 1 , wherein each A is SO 3 H.
4. The method of claim 1 , wherein Compound B is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of Compound A, Compound B, and Compound C.
5. The method of claim 1 , wherein Compound C is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of Compound A, Compound B, and Compound C.
6. A method of treating pain, comprising administering a dosage form to a mammal in need thereof, comprising:
zoledronic acid,
and
7. The method of claim 6 , wherein Compound 1 is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
8. The method of claim 6 , wherein Compound 1 is present in the dosage form in an amount that is less than about 0.05% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
9. The method of claim 6 , wherein Compound 1 is present in the dosage form in an amount that is less than about 0.02% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
10. The method of claim 6 , wherein Compound 2 is present in the dosage form in an amount that is less than 0.1% w/w and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
11. The method of claim 6 , wherein Compound 2 is present in the dosage form in an amount that is less than about 0.05% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
12. The method of claim 6 , wherein Compound 2 is present in the dosage form in an amount that is less than about 0.02% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
13. The method of claim 8 , wherein Compound 2 is present in the dosage form in an amount that is less than about 0.05%, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
14. The method of claim 6 , wherein the zoledronic acid is present in the dosage form in a salt form.
15. The method of claim 14 , wherein the zoledronic acid is present in the dosage form in a sodium salt form.
16. The method of claim 14 , wherein the zoledronic acid is present in the dosage form in a disodium salt form.
17. The method of claim 6 , wherein the dosage form is administered orally.
18. The method of claim 17 , wherein Compound 1 is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
19. The method of claim 17 , wherein Compound 2 is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
20. A method of treating a disease or condition related to pain, bone, or cancer comprising administering an oral dosage form to a mammal in need thereof, comprising:
zoledronic acid,
and
wherein the disease or condition related to pain, bone or cancer is inflammatory pain, arthritis pain, complex regional pain syndrome, lumbosacral pain, musculoskeletal pain, neuropathic pain, chronic pain, cancer-related pain, acute pain, postoperative pain, low back pain, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, a sero-negative or non-rheumatoid arthropathy, non-articular rheumatism, a peri-articular disorder, axial spondyloarthritis, ankylosing spondylitis, Paget's disease of bone, fibrous dysplasia, SAPHO syndrome, transient osteoarthritis of the hip, pain associated with vertebral crush fractures, osteoporosis, neuropathic pain, diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, monoradiculopathies, phantom limb pain, central pain, cancer-related pain, lumbar nerve root compression, spinal cord injury, post-stroke pain, central multiple sclerosis pain, HIV-associated neuropathy, radio-therapy associated neuropathy, chemo-therapy associated neuropathy, or a combination thereof.
21. The method of claim 20 , wherein Compound 1 is present in the dosage form in an amount that is less than 0.1% w/w, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
22. The method of claim 20 , wherein Compound 1 is present in an amount that is less than about 0.02% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
23. The method of claim 20 , wherein Compound 2 is present in an amount that is less than 0.1% w/w and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
24. The method of claim 20 , wherein Compound 2 is present in an amount that is less than about 0.02% and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
25. The method of claim 21 , wherein Compound 2 is present in an amount that is less than about 0.1%, and greater than 0% w/w, based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
26. The method of claim 6 , wherein the zoledronic acid is present in a salt form.
27. The method of claim 13 , wherein the zoledronic acid is present in a sodium salt form.
28. The method of claim 14 , wherein the zoledronic acid is present in a disodium salt form.